Waltham, MA, United States
Waltham, MA, United States

Time filter

Source Type

News Article | May 8, 2017
Site: globenewswire.com

MIAMI, May 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months ended March 31, 2017, after the close of the U.S. financial markets on Tuesday, May 9, 2017. OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, May 9, 2017. For those unable to participate in the live conference call or webcast, a replay will be available beginning May 9, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 17226044. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.


News Article | May 4, 2017
Site: www.prlog.org

-- WOW Women Network (www.wwntwk.com), a place where great women gather informally to ignite relationships and build connections, held the monthly Coffee & Connections Networking event earlier this week at PTC in Needham.  The event was attended by over 60 women connected either through PTC's Women of PTC ERG or WWN, and was hosted by Super Connectors Kathy Cullen-Cote and Colleen Simonelli, both of PTC.Nettie Nitzberg, a recognized expert in helping global companies maximize their people investments and founder and principal of West5 Consulting (www.west5consulting.com), as well as founder of the WOW Women Network, facilitated the networking event, which featured an innovative networking style program that ditches the typical business networking protocols and instead delivers a truly unique connection-building experience.  Informal networking opportunities were also offered before the orchestrated program began.Attendees enjoyed the Ripple exercises and left the event with helpful strategies for future networking events.  Karen Gobler, principal at Vital Link, said, "The Ripple questions not only helped me think introspectively, but also connect with others at a deeper level. …You've empowered me with vital tools for navigating future events."  Cindy Loughran of Cindy Loughran Coaching, added, "[The] WOW networking event was great!...I appreciate you doing them and attracting such a great collection of women….I loved today's questions…It is such a great exercise.""We loved being joined by so many PTC women, and again express our gratitude to Kathy Cullen-Cote and Colleen Simonelli at PTC for stepping up and hosting this event!" said Nitzberg.  "And we're looking forward to meeting more fabulous women at additional upcoming events, currently planned for June, September, October and November," added Nitzberg.Nettie Nitzberg founded WOW Women in 2015 as a result of combining her love of connecting with her passion for supporting the success of women in business.  Now known as WOW Women Network, the organization's mission is to offer fun and creative ways to build connections and for women to get to know each other at a deeper level.  WWN events include Coffee & Connections (frequent morning events), Cocktails & Connections (casual, after-work morning events) and Community & Connections (opportunities to come together to offer service to a local organization providing help and support to women in crisis; usually once or twice a year).In addition, the WOW Women Network holds special events periodically, as well as quarterly Ripple Events, which feature an innovative networking style that ditches the typical business networking protocols and instead delivers a truly unique connection-building experience.Information about all of these events, as well as additional background on the organization and how to join, is available on the website, www.wwntwk.com West5 Consulting is a people and organization development company that is dedicated to solving people problems that impact business success.  Principal Nettie Nitzberg help clients optimize their processes for selecting, integrating and developing their most important resource – people, by creating work environments that attract, grow and retain top talent. West5 Consulting understands that the process starts, rather than ends, with a new hire. Their services include management and leadership development, onboarding, team building, culture, and more. Clients include PerkinElmer, PTC, JPMorgan Chase, TESARO, Babson College,McGraw-Hill Education, and Biogen, among others. Industries of interest include pharmaceutical, biomedical/biotechnology, higher education, finance, professional services, technology and non-profit organizations.  For additional information, please visit www.west5consulting.com or call 678-438-4803.


CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by TESARO, Inc. to be a specialty pharmacy provider in the distribution network for ZEJULA.


WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos Verdes, California. Tim Pearson, EVP and CFO of TESARO, will present at 10:40 AM PT on June 15 and will participate in meetings with investors. A live webcast of the presentation will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences. About TESARO TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.


WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos Verdes, California. Tim Pearson, EVP and CFO of TESARO, will present at 10:40 AM PT on June 15 and will participate in meetings with investors. A live webcast of the presentation will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences. About TESARO TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.


WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos Verdes, California. Tim Pearson, EVP and CFO of TESARO, will present at 10:40 AM PT on June 15 and will participate in meetings with investors. A live webcast of the presentation will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences. About TESARO TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.


News Article | June 16, 2017
Site: www.prweb.com

Anyone who has been diagnosed with cancer or who has known someone who has been diagnosed is aware of the mental, physical and emotional toll the disease will take through diagnosis and treatment. Ovarian cancer is no exception, and with more than 22,000 women in the U.S. projected to be diagnosed with ovarian cancer annually, there needs to be a better understanding of the disease. Ovarian cancer is the 5th leading cause of cancer death in American women. A video accompanying this announcement is available at: https://youtu.be/_ZIDB_EZbCo To identify the unmet education and support needs of the advanced ovarian cancer community, TESARO developed the Our Way Forward survey, with input from the National Ovarian Cancer Coalition (NOCC) and the Ovarian Cancer Research Fund Alliance (OCRFA); the organizations helped promote the survey to patients and oncologists. This national survey found regardless of the stage of ovarian cancer, there is uncertainty among patients about what to expect after diagnosis – whether they are initially diagnosed or actively seeking greater resources and connections to lessen the burden of the disease. In conjunction with D S Simon Media and YourUpdate.TV, Tesaro Inc. worked with Stephanie V. Blank, MD, Professor in the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, and Director of Women's Health, Mount Sinai Downtown-Chelsea Center and Anne Sweeney, Massachusetts Chapter Manager, National Ovarian Cancer Coalition, wife, mother and ovarian cancer thriver on a media tour to bring awareness to the Our Way Forward campaign. Dr. Blank and Anne spoke to television and radio stations across the country and were able to address: About the Our Way Forward Survey: The Our Way Forward survey was conducted online in the U.S. by Harris Poll on behalf of Tesaro, Inc. between April 2017 and May 2017 among 254 women 18+ years of age living in the U.S. who have been diagnosed with ovarian cancer. Survey respondents were selected from individuals who had agreed to participate in surveys through the Harris Poll and their partners or were recruited to participate by patient advocacy organizations, NOCC and OCRFA. Results are not weighted and are therefore representative of only those surveyed. A parallel survey was conducted between April 2017 and May 2017 among 232 physicians who treat ovarian cancer patients in the U.S. including 201 medical oncologists and 31 gynecologic oncologists. Survey respondents were selected from physicians who had agreed to participate in surveys through the Harris Poll and their partners. Weights for gender by years in practice and region were applied to align the data with the population parameters for medical oncologists and gynecologic oncologists, separately. A post weight was then applied to combine the two medical specialty groups in proper proportion for the total. More information about the campaign and survey findings, including important resources to enhance conversations about ovarian cancer are available on the Our Way Forward website at http://www.ourwayforward-oc.com and via NOCC and OCRFA. About Ovarian Cancer: Approximately 22,000 women are diagnosed with ovarian cancer each year in the United States, and more than 65,000 women are diagnosed annually in Europe. Ovarian cancer is the fifth-most frequent cause of cancer death among women. Despite high response rates to platinum-based chemotherapy in the second-line advanced treatment setting, approximately 85 percent of patients will experience recurrence within two years. About TESARO:  TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit http://www.tesarobio.com, and follow us on Twitter and LinkedIn. About YourUpdateTV:  YourUpdateTV is a social media video portal for organizations to share their content, produced by award-winning video communications firm, D S Simon Media (http://www.dssimon.com). It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology.


News Article | July 25, 2017
Site: globenewswire.com

WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2017 financial results on Tuesday, August 8, 2017, after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on August 8, 2017 to discuss the Company’s operating results in greater detail, as well as the status of its development programs and the VARUBI/Y® and ZEJULATM launches. This quarterly earnings call will be available via phone and webcast. The conference call dial-in information is listed below. To access the webcast, please log on to the TESARO website at www.tesarobio.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. TESARO will host a conference call and live audio webcast to discuss its second-quarter financial results. WHEN: Tuesday, August 8, 2017 at 4:15 p.m. ET LIVE DOMESTIC & CANADA CALL-IN: (877) 853-5334 LIVE INTERNATIONAL CALL-IN: (970) 315-0307 THIS CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT: www.tesarobio.com A replay will be available for 30 days at www.tesarobio.com. TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.


Patent
Tesaro and Myriad Genetics Inc. | Date: 2015-12-08

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided.


Patent
Tesaro | Date: 2012-11-13

The present invention provides therapeutic and diagnostic modalities relevant to treating disorders associated with tyrosine kinase activity.

Loading TESARO collaborators
Loading TESARO collaborators